Press Releases Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
22.73 ^USD	-0.96%		+6.31%	-25.45%

Jun. 03	Intellia Therapeutics Shares Rise as NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate	MT
Jun. 03	Transcript : Intellia Therapeutics, Inc. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema	Jun. 03	AQ
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)	Jun. 02	AQ
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress	May. 09	AQ
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates	May. 02	AQ
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024	Apr. 29	AQ
Intellia Therapeutics : Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - Form 8-K	Apr. 15	PU
Intellia Therapeutics : Termination of Material Agreement - Form 8-K	Mar. 22	PU
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	Mar. 18	AQ
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress	Feb. 22	AQ
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	Feb. 15	BU
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	Feb. 15	AQ
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	Feb. 14	AQ
AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy	Feb. 07	AQ
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine	Jan. 31	AQ
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones	Jan. 04	AQ
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema	Nov. 15	AQ
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema	Nov. 14	AQ
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress	Nov. 09	AQ
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting	Nov. 02	AQ
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November	23-10-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Press Releases

Filters